Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
Blueprint Medicines Corporation Stock Forecast NASDAQ:BPMC
Price Target and Analyst Ratings
Historical Ratings
| Date | Upside / Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 2022-04-13 | 20.97% | Citigroup | $71.00 $68.00 | Maintains | Neutral |
| 2022-03-04 | 86.8% | Stifel | $100.00 $105.00 | Maintains | Buy |
| 2022-03-01 | - | Citigroup | - | Initiates Coverage On | Neutral |
| 2022-02-17 | 77.9% | HC Wainwright & Co. | $135.00 $100.00 | Maintains | Buy |
| 2022-02-17 | 45.88% | SVB Leerink | $93.00 $82.00 | Downgrades | Outperform Market Perform |
| 2022-02-01 | 63.67% | Morgan Stanley | $111.00 $92.00 | Maintains | Equal-Weight |
| 2022-01-25 | 69.01% | Stifel | $120.00 $95.00 | Upgrades | Hold Buy |
| 2022-01-12 | 113.49% | SVB Leerink | $132.00 $120.00 | Maintains | Outperform |
| 2021-11-10 | 136.61% | Raymond James | $122.00 $133.00 | Maintains | Strong Buy |
| 2021-10-29 | 97.47% | Morgan Stanley | $96.00 $111.00 | Maintains | Equal-Weight |
| 2021-07-30 | 70.79% | Morgan Stanley | $101.00 $96.00 | Maintains | Equal-Weight |
| 2021-06-17 | 118.82% | Baird | $119.00 $123.00 | Maintains | Outperform |
| 2021-06-17 | 143.73% | SVB Leerink | $127.00 $137.00 | Maintains | Outperform |
| 2021-06-17 | 131.28% | Wedbush | $136.00 $130.00 | Maintains | Outperform |
| 2021-04-30 | 79.68% | Morgan Stanley | $105.00 $101.00 | Maintains | Equal-Weight |
| 2021-04-13 | 141.95% | Wedbush | $119.00 $136.00 | Maintains | Outperform |
| 2021-03-31 | 77.9% | Credit Suisse | $100.00 | Initiates Coverage On | Neutral |
| 2021-02-18 | 69.01% | Barclays | $90.00 $95.00 | Maintains | Equal-Weight |
| 2021-02-18 | 86.8% | Morgan Stanley | $112.00 $105.00 | Maintains | Equal-Weight |
| 2021-01-12 | 125.94% | SVB Leerink | $121.00 $127.00 | Maintains | Outperform |
| 2020-12-03 | 95.69% | Stifel | $110.00 | Initiates Coverage On | Hold |
| 2020-11-02 | 70.79% | Jefferies | $96.00 | Downgrades | Buy Hold |
| 2020-10-30 | - | Morgan Stanley | - | Downgrades | Overweight Equal-Weight |
| 2020-10-16 | 117.04% | Raymond James | $106.00 $122.00 | Maintains | Strong Buy |
| 2020-10-13 | 77.9% | Morgan Stanley | $92.00 $100.00 | Maintains | Overweight |
| 2020-07-27 | 90.36% | SVB Leerink | $106.00 $107.00 | Maintains | Outperform |
| 2020-07-15 | 63.67% | Morgan Stanley | $88.00 $92.00 | Maintains | Overweight |
| 2020-07-15 | 95.69% | HC Wainwright & Co. | $66.00 $110.00 | Maintains | Buy |
| 2020-07-15 | 88.58% | SVB Leerink | $105.00 $106.00 | Maintains | Outperform |
| 2020-06-08 | 51.22% | Deutsche Bank | $70.00 $85.00 | Maintains | Buy |
| 2020-05-05 | 4.96% | Barclays | $59.00 | Initiates Coverage On | Equal-Weight |
| 2020-04-30 | 56.56% | Morgan Stanley | $103.00 $88.00 | Maintains | Overweight |
| 2020-04-30 | 77.9% | Canaccord Genuity | $115.00 $100.00 | Maintains | Buy |
| 2020-04-29 | 33.43% | BMO Capital | $89.00 $75.00 | Maintains | Outperform |
| 2020-04-29 | 17.42% | HC Wainwright & Co. | $100.00 $66.00 | Reiterates | Buy |
| 2020-04-29 | 86.8% | SVB Leerink | $125.00 $105.00 | Maintains | Outperform |
| 2020-04-29 | 83.24% | JMP Securities | $107.00 $103.00 | Maintains | Market Outperform |
| 2020-03-17 | 58.33% | BMO Capital | $74.00 $89.00 | Upgrades | Market Perform Outperform |
| 2020-03-17 | 24.53% | Deutsche Bank | $70.00 | Upgrades | Hold Buy |
| 2020-02-18 | 83.24% | Morgan Stanley | $108.00 $103.00 | Maintains | Overweight |
| 2020-01-28 | 31.65% | BMO Capital | $74.00 | Initiates Coverage On | Market Perform |
| 2019-12-10 | 24.53% | Deutsche Bank | $75.00 $70.00 | Maintains | Hold |
| 2019-11-06 | 92.14% | Morgan Stanley | $109.00 $108.00 | Maintains | Overweight |
| 2019-11-06 | - | Raymond James | - | Upgrades | Outperform Strong Buy |
| 2019-10-29 | 33.43% | Deutsche Bank | $110.00 $75.00 | Downgrades | Buy Hold |
| 2019-10-11 | 93.92% | Morgan Stanley | $110.00 $109.00 | Maintains | Overweight |
| 2019-10-03 | 77.9% | HC Wainwright & Co. | $100.00 | Initiates Coverage On | Buy |
| 2019-09-12 | - | Raymond James | - | Upgrades | Market Perform Outperform |
| 2019-08-29 | 51.22% | Piper Sandler | $85.00 | Initiates Coverage On | Neutral |
| 2019-08-15 | - | Raymond James | - | Reinstates | Market Perform |
| 2019-07-19 | 113.49% | Baird | $120.00 | Initiates Coverage On | Outperform |
| 2019-07-18 | 95.69% | Deutsche Bank | $110.00 | Initiates Coverage On | Buy |
| 2019-05-23 | 122.38% | Goldman Sachs | $125.00 | Assumes | Buy |
BPMC Stock Trend
The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.
Given the current short-term trend, the stock is expected to fall -4.29% during the next 3 months and, with a 90% probability hold a price between $49.36 and $66.04 at the end of this 3-month period.
WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.
Data
| Date | Bottom | Mid | Top |
|---|---|---|---|
| 2022-05-18 | $51.53 | $60.24 | $68.95 |
| 2022-05-19 | $51.47 | $60.19 | $68.90 |
| 2022-05-20 | $51.42 | $60.13 | $68.85 |
| 2022-05-23 | $51.37 | $60.08 | $68.80 |
| 2022-05-24 | $51.32 | $60.03 | $68.74 |
| 2022-05-25 | $51.27 | $59.98 | $68.69 |
| 2022-05-26 | $51.22 | $59.93 | $68.64 |
| 2022-05-27 | $51.16 | $59.88 | $68.59 |
| 2022-05-31 | $51.11 | $59.83 | $68.54 |
| 2022-06-01 | $51.06 | $59.77 | $68.49 |
| 2022-06-02 | $51.01 | $59.72 | $68.44 |
| 2022-06-03 | $50.96 | $59.67 | $68.38 |
| 2022-06-06 | $50.91 | $59.62 | $68.33 |
| 2022-06-07 | $50.86 | $59.57 | $68.28 |
| 2022-06-08 | $50.80 | $59.52 | $68.23 |
| 2022-06-09 | $50.75 | $59.47 | $68.18 |
| 2022-06-10 | $50.70 | $59.41 | $68.13 |
| 2022-06-13 | $50.65 | $59.36 | $68.08 |
| 2022-06-14 | $50.60 | $59.31 | $68.02 |
| 2022-06-15 | $50.55 | $59.26 | $67.97 |
| 2022-06-16 | $50.50 | $59.21 | $67.92 |
| 2022-06-17 | $50.44 | $59.16 | $67.87 |
| 2022-06-21 | $50.39 | $59.11 | $67.82 |
| 2022-06-22 | $50.34 | $59.05 | $67.77 |
| 2022-06-23 | $50.29 | $59.00 | $67.71 |
| 2022-06-24 | $50.24 | $58.95 | $67.66 |
| 2022-06-27 | $50.19 | $58.90 | $67.61 |
| 2022-06-28 | $50.13 | $58.85 | $67.56 |
| 2022-06-29 | $50.08 | $58.80 | $67.51 |
| 2022-06-30 | $50.03 | $58.74 | $67.46 |
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. Its lead drug candidates include BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patie... Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Join 108 000+ Happy Subscribers
Don't miss out on the runners!
![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
